Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 81

Sort by

Sort Order Select

Journal Articles

Randomized Phase III Study of Watchful Waiting Vs. Rituximab As First-Line Treatment in Patients with Advanced Stage Low Tumor Burden Follicular Lymphoma: JCOG1411/Flora Study

Blood (2024) 144 (Supplement 1): 338.

https://doi.org/10.1182/blood-2024-199868

Published: 2024

Journal Articles

The Anti-Myeloma Efficacy of TAS0612, a Triple Inhibitor of RSK, AKT, and S6K, and Itssynergistic Combination with Venetoclax in Multiple Myeloma Irrespective of Cytogeneticabnormalities

Haruya Okamoto, Shinsuke Mizutani, Taku Tsukamoto, Yoko Katsuragawa-Taminishi, Yuka Kawaji-Kanayama, Kentaro Mizuhara, Ayako Muramatsu, Reiko Isa, Takahiro Fujino, Yuji Shimura, Koji Ichikawa, Junya Kuroda

Blood (2024) 144 (Supplement 1): 4178.

https://doi.org/10.1182/blood-2024-199695

Published: 2024

Journal Articles

Trends and Outcomes of Hematopoietic Stem Cell Transplantation for Malignant Lymphoma in Japan between 2006 and 2021

Blood (2024) 144 (Supplement 1): 4472.

https://doi.org/10.1182/blood-2024-206515

Published: 2024

Journal Articles

MagnetisMM-9: Efficacy and Safety of Step-up Priming Doses and Longer Dosing Intervals of Elranatamab (ELRA) in Patients with Relapsed or Refractory Multiple Myeloma (RRMM)

Matthew Pianko, Charlotte Pawlyn, Shang-Yi Huang, Tadao Ishida, Douglas W Sborov, Shinsuke Iida, Aravind Ramakrishnan, Reuben Benjamin, Rakesh Popat, Steven Schuster, Junya Kuroda, Chia-Jen Liu, Anne Philippe, Umberto Conte, Fangxin Hong, Erik Vandendries, Rafael Fonseca

Blood (2024) 144 (Supplement 1): 4743.

https://doi.org/10.1182/blood-2024-205872

Published: 2024

Journal Articles

Real-World (RW) Treatment (Tx) Patterns and Outcomes in Patients (Pts) with Relapsed/Refractory Multiple Myeloma (RRMM) Previously Treated with Lenalidomide and an Anti-CD38 Monoclonal Antibody: Data from the Japan Medical Data Vision Database

Junya Kuroda, Teofilia Acheampong, Mayuko Nakakoji, Tohru Miyazaki, Ryosuke Hinosugi, Shigeki Kuwayama, Yu-Hsuan Shih

Blood (2024) 144 (Supplement 1): 7894.

https://doi.org/10.1182/blood-2024-198399

Published: 2024

Journal Articles

AML-Mrg Mutation Spectrum and Its Prognosis: A Japanese Multicenter Study HM01-02 Analysis with Full Analysis Sets

Blood (2024) 144 (Supplement 1): 6123.

https://doi.org/10.1182/blood-2024-202327

Published: 2024

Journal Articles

ctDNA improves prognostic prediction for patients with relapsed/refractory MM receiving ixazomib, lenalidomide, and dexamethasone

Blood (2024) 143 (23): 2401–2413.

https://doi.org/10.1182/blood.2023022540

Published: 2024

Includes: Supplemental data

Journal Articles

The Activation Status of RSK2, but Not PDPK1 and AKT, Associates with the Prognosis of Diffuse Large B Cell Lymphoma

Akio Onishi, Aya Miyagawa-Hayashino, Kentaro Mizuhara, Ayako Muramatsu, Haruya Okamoto, Yuka Kawaji-Kanayama, Yoko Katsuragawa-Taminishi, Takahiro Fujino, Taku Tsukamoto, Shinsuke Mizutani, Yuji Shimura, Eiichi Konishi, Junya Kuroda

Blood (2023) 142 (Supplement 1): 4390.

https://doi.org/10.1182/blood-2023-184365

Published: 2023

Journal Articles

A Phase 1 Trial of OPB-111077 in Combination with Bendamustine (B) and Rituximab (R) in Patients with Relapsed or Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL): Preliminary Results of Dose-Escalation Stage

Tomomi Toubai, Junya Kuroda, Youko Suehiro, Yuko Mishima, Kazutaka Sunami, Koji Kato, Nobuhiko Uoshima, Takahiro Kumode, Ai Ota, Kaori Mitsuki, Daisuke Yokota, Yuri Sano, Yasuhito Terui

Blood (2023) 142 (Supplement 1): 4464.

https://doi.org/10.1182/blood-2023-179716

Published: 2023

Journal Articles

An Open-Label, Multicenter, Single-Arm, Phase I Dose Escalation Study of OP-2100, an Orally Bioavailable Prodrug of Decitabine, for Patients with Relapsed or Refractory Higher-Risk Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia

Shinya Kimura, Kensuke Usuki, Tatsuo Ichinohe, Takayuki Ikezoe, Junya Kuroda, Senji Kasahara, Sho Okamoto, Hiromitsu Iizuka, Hiroshi Ureshino, Tatsuro Watanabe, Tokihiro Ro, Kosuke Endo, Yuka Kagawa, Yuki Kurahashi, Toshiki Naito, Takahiro Yamauchi

Blood (2023) 142 (Supplement 1): 6466.

https://doi.org/10.1182/blood-2023-173174

Published: 2023

Journal Articles

NGS Profile and the Mathematical Prediction Model for Venetoclax Combination Therapy in HM-Screen-Japan 02 Study

Tomoaki Ueda, Kentaro Fukushima, Naoki Hosen, Sunggi Chi, Hiroshi Haeno, Goichi Yoshimoto, Hironori Arai, Daisuke Ikeda, Kensuke Usuki, Naoto Takahashi, Naoko Hosono, Takahiro Yamauchi, Takeshi Kondo, Kazuhito Yamamoto, Junya Kuroda, Yosuke Minami

Blood (2023) 142 (Supplement 1): 5761.

https://doi.org/10.1182/blood-2023-180339

Published: 2023

Journal Articles

TAS0612, a Triple Inhibitor for RSK, AKT, and S6K, Is a Promising Anti-Myeloma Agent Regardless of Types of Cytogenetic/Genetic Abnormality

Haruya Okamoto, Shinsuke Mizutani, Taku Tsukamoto, Yoko Katsuragawa-Taminishi, Reiko Isa, Kentaro Mizuhara, Ayako Muramatsu, Yuka Kawaji-Kanayama, Takahiro Fujino, Yuji Shimura, Junya Kuroda

Blood (2023) 142 (Supplement 1): 3313.

https://doi.org/10.1182/blood-2023-174157

Published: 2023

Journal Articles

Final Analysis of the Randomized Phase II/III Study of Standard R-CHOP Versus CHOP Combined with Dose-Dense Weekly Rituximab for DLBCL: JCOG0601

Blood (2023) 142 (Supplement 1): 1724.

https://doi.org/10.1182/blood-2023-178551

Published: 2023

Journal Articles

The Universal Antitumor Activity of TAS0612, a Triple Inhibitor for RSK, AKT, and S6K, in B-Cell Lymphomas Regardless of Disease Subtype

Yoko Katsuragawa-Taminishi, Shinsuke Mizutani, Yuka Kawaji-Kanayama, Akio Onishi, Haruya Okamoto, Reiko Isa, Kentaro Mizuhara, Ayako Muramatsu, Takahiro Fujino, Taku Tsukamoto, Yuji Shimura, Masafumi Taniwaki, Aya Miyagawa-Hayashino, Eiichi Konishi, Junya Kuroda

Blood (2023) 142 (Supplement 1): 7135.

https://doi.org/10.1182/blood-2023-173485

Published: 2023

Journal Articles

Mutational Analysis of DNMT3A Improves the Prognostic Stratification Using NPM1 / FLT3 -ITD Genotypes in Patients with Acute Myeloid Leukemia

Blood (2022) 140 (Supplement 1): 8914–8916.

https://doi.org/10.1182/blood-2022-158686

Published: 2022

Journal Articles

Final Analysis of JCOG0203 for Advanced-Stage Indolent B-Cell Lymphoma 15 Years after the End of Enrollment: Pooled Analysis of Arms a and B for Follicular Lymphoma

Takashi Watanabe, Kensei Tobinai, Ｍasashi Wakabayashi, Dai Maruyama, Kazuhito Yamamoto, Nobuko Kubota, Kazuyuki Shimada, Kohsuke Asagoe, Motoko Yamaguchi, Kiyoshi Ando, Michinori Ogura, Junya Kuroda, Youko Suehiro, Yoshihiro Matsuno, Kunihiro Tsukasaki, Hirokazu Nagai

Blood (2022) 140 (Supplement 1): 3615–3617.

https://doi.org/10.1182/blood-2022-159967

Published: 2022

Journal Articles

Mir-106a-5p and Mir-146a-5p Delivered By Tumor-Derived Exosomes Promote the Induction of Myeloid-Derived Suppressor Cells from Normal Peripheral Blood Mononuclear Cells in Multiple Myeloma

Kentaro Mizuhara, Yuji Shimura, Taku Tsukamoto, Akinori Kanai, Saeko Kuwahara-Ota, Junko Yamaguchi, Ayako Muramatsu, Haruya Okamoto, Yoko Katsuragawa-Taminishi, Yuka Kawaji-Kanayama, Reiko Isa, Shinsuke Mizutani, Toshiya Inaba, Junya Kuroda

Blood (2022) 140 (Supplement 1): 9949–9950.

https://doi.org/10.1182/blood-2022-160408

Published: 2022

Journal Articles

Nutritional and Cytogenetic Assessment Predicts Favorable Response to Azacitidine Monotherapy for Myelodysplastic Syndromes

Haruya Okamoto, Yu Inoue, Akihiro Miyashita, Yuka Kawaji-Kanayama, Shotaro Chinen, Takahiro Fujino, Taku Tsukamoto, Yuji Shimura, Shinsuke Mizutani, Hiroto Kaneko, Saeko Kuwahara, Shin-ichi Fuchida, Daichi Nishiyama, Koichi Hirakawa, Junya Kuroda

Blood (2022) 140 (Supplement 1): 12321–12322.

https://doi.org/10.1182/blood-2022-157863

Published: 2022

Journal Articles

Genomic Analysis of NPM1 Mutation and KMT2A ( MLL )-Rearrangement/Amplification in Japanese Patients with Acute Myeloid Leukemia: Hematologic Malignancies (HM)-Screen-Japan 01

Blood (2021) 138 (Supplement 1): 4460.

https://doi.org/10.1182/blood-2021-149425

Published: 2021

Journal Articles

Properties and Distribution of IDH-1/2 Mutations in Acute Myeloid Leukemia By the Comprehensive Genomic Analysis

Blood (2021) 138 (Supplement 1): 4447.

https://doi.org/10.1182/blood-2021-149801

Published: 2021

NARROW

Randomized Phase III Study of Watchful Waiting Vs. Rituximab As First-Line Treatment in Patients with Advanced Stage Low Tumor Burden Follicular Lymphoma: JCOG1411/Flora Study

The Anti-Myeloma Efficacy of TAS0612, a Triple Inhibitor of RSK, AKT, and S6K, and Itssynergistic Combination with Venetoclax in Multiple Myeloma Irrespective of Cytogeneticabnormalities

Trends and Outcomes of Hematopoietic Stem Cell Transplantation for Malignant Lymphoma in Japan between 2006 and 2021

MagnetisMM-9: Efficacy and Safety of Step-up Priming Doses and Longer Dosing Intervals of Elranatamab (ELRA) in Patients with Relapsed or Refractory Multiple Myeloma (RRMM)

Real-World (RW) Treatment (Tx) Patterns and Outcomes in Patients (Pts) with Relapsed/Refractory Multiple Myeloma (RRMM) Previously Treated with Lenalidomide and an Anti-CD38 Monoclonal Antibody: Data from the Japan Medical Data Vision Database

AML-Mrg Mutation Spectrum and Its Prognosis: A Japanese Multicenter Study HM01-02 Analysis with Full Analysis Sets

ctDNA improves prognostic prediction for patients with relapsed/refractory MM receiving ixazomib, lenalidomide, and dexamethasone

The Activation Status of RSK2, but Not PDPK1 and AKT, Associates with the Prognosis of Diffuse Large B Cell Lymphoma

A Phase 1 Trial of OPB-111077 in Combination with Bendamustine (B) and Rituximab (R) in Patients with Relapsed or Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL): Preliminary Results of Dose-Escalation Stage

An Open-Label, Multicenter, Single-Arm, Phase I Dose Escalation Study of OP-2100, an Orally Bioavailable Prodrug of Decitabine, for Patients with Relapsed or Refractory Higher-Risk Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia

NGS Profile and the Mathematical Prediction Model for Venetoclax Combination Therapy in HM-Screen-Japan 02 Study

TAS0612, a Triple Inhibitor for RSK, AKT, and S6K, Is a Promising Anti-Myeloma Agent Regardless of Types of Cytogenetic/Genetic Abnormality

Final Analysis of the Randomized Phase II/III Study of Standard R-CHOP Versus CHOP Combined with Dose-Dense Weekly Rituximab for DLBCL: JCOG0601

The Universal Antitumor Activity of TAS0612, a Triple Inhibitor for RSK, AKT, and S6K, in B-Cell Lymphomas Regardless of Disease Subtype

Mutational Analysis of DNMT3A Improves the Prognostic Stratification Using NPM1 / FLT3 -ITD Genotypes in Patients with Acute Myeloid Leukemia

Final Analysis of JCOG0203 for Advanced-Stage Indolent B-Cell Lymphoma 15 Years after the End of Enrollment: Pooled Analysis of Arms a and B for Follicular Lymphoma

Mir-106a-5p and Mir-146a-5p Delivered By Tumor-Derived Exosomes Promote the Induction of Myeloid-Derived Suppressor Cells from Normal Peripheral Blood Mononuclear Cells in Multiple Myeloma

Nutritional and Cytogenetic Assessment Predicts Favorable Response to Azacitidine Monotherapy for Myelodysplastic Syndromes

Genomic Analysis of NPM1 Mutation and KMT2A ( MLL )-Rearrangement/Amplification in Japanese Patients with Acute Myeloid Leukemia: Hematologic Malignancies (HM)-Screen-Japan 01

Properties and Distribution of IDH-1/2 Mutations in Acute Myeloid Leukemia By the Comprehensive Genomic Analysis

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only